Page 9 - Compass Pathways News Today

Unlock the Potential: Dive into the Future of Psychedelic Healthcare Investments with Compass Pathways (CMPS). As Big Pharma Takes Notice, Citadel Advisors Secures a 4.9% Stake. Positive Phase II Trial Results Propel CMPS Towards a Psychological Trigger at $10. Explore the Playbook Unfolding in the Psychedelic Industry. #PsychedelicInvesting #CMPS #HealthcareStocks

Series A funding raises more than $100 million for MAPS amid a flurry of deals by competitors

Biotechnology company Compass Pathways plc CMPS and Greenbrook TMS Inc GBNH have entered into a three-year research collaboration agreement to explore…

Biotechnology company Compass Pathways plc (NASDAQ: CMPS) and Greenbrook TMS Inc (NASDAQ: GBNH) have entered into a three-year research collaboration agreement to explore delivery models 

BioPharma

Biotechnology company Compass Pathways plc (NASDAQ:CMPS) and Greenbrook TMS Inc (NASDAQ:GBNH) have entered into a three-year r...

A financial backer of the effort to legalize the drug MDMA for therapeutic use sees the potential for "exponential growth" should it win approval from the...

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 4,350,000 shares, an increase of 12.7% from the November 30th total of 3,860,000 shares. Based on an average daily volume of 526,000 shares, the short-interest ratio […]

Initial data from phase 2 safety profile for psilocybin in the treatment of PTSD indicates the treatment is well-tolerated.

Shares of COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued a report on the […]